PD
FOLD

Point72 (DIFC)’s Amicus Therapeutics FOLD Stock Holding History

Point72 (DIFC)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$275K Sell
34,876
-20,292
-37% -$144K 0.02% 387
2025
Q2 		$316K Buy
55,168
+6,107
+12% +$39.4K 0.01% 690
2025
Q1 		$400K Buy
+49,061
New +$454K 0.02% 700
2024
Q4 		– Sell
-65,925
Closed -$704K – 1648
2024
Q3 		$704K Buy
+65,925
New +$718K 0.02% 567
2024
Q2 		– Sell
-43,178
Closed -$509K – 1607
2024
Q1 		$509K Buy
+43,178
New +$552K 0.02% 738

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Point72 (DIFC)'s FOLD Position: Q3 2025 in Review

Point72 (DIFC) reduced its Amicus Therapeutics (FOLD) stake by 37% in Q3 2025, selling an estimated $144K and leaving 34,876 shares worth $275K. The position accounts for 0.02% of the portfolio, ranked #387.

Point72 (DIFC) first reported a position in FOLD in Q1 2024 and has held it in 5 quarters since. The position peaked at $704K in Q3 2024. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Point72 (DIFC) held 34,876 shares of Amicus Therapeutics worth $275K as of Q3 2025.
  • Point72 (DIFC) sold 20,292 Amicus Therapeutics shares in Q3 2025, an estimated $144K.
  • Amicus Therapeutics made up 0.02% of Point72 (DIFC)'s portfolio in Q3 2025, its #387 holding.
  • Point72 (DIFC) first reported a position in Amicus Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Point72 (DIFC)'s Amicus Therapeutics position peaked at $704K in Q3 2024.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.